Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Neoadjuvant-Adjuvant vs Neoadjuvant-Only PD-1 and PD-L1 Inhibitors for Patients With Resectable NSCLC
Yixin Zhou, Anlin Li, Hui Yu, et al.
JAMA Network Open (2024) Vol. 7, Iss. 3, pp. e241285-e241285
Open Access | Times Cited: 19

Showing 19 citing articles:

Programmed death receptor (PD-)1/PD-ligand (L)1 in urological cancers : the “all-around warrior” in immunotherapy
Qiang Liu, Yujing Guan, Shenglong Li
Molecular Cancer (2024) Vol. 23, Iss. 1
Open Access | Times Cited: 16
Patients With Resectable NSCLC Undergoing Neoadjuvant Chemoimmunotherapy: To Adjuvant or Not to Adjuvant?
Peng Wu, Dongyu Li, Chaoqi Zhang, et al.
Journal of Thoracic Oncology (2025) Vol. 20, Iss. 3, pp. e41-e42
Closed Access | Times Cited: 2
Perioperative or neo/adjuvant chemoimmunotherapy versus chemotherapy for resectable non-small cell lung cancer: a systematic review and network meta-analysis
Qiong Zhang, Jia Duan, Yuanmei Zhang, et al.
Systematic Reviews (2025) Vol. 14, Iss. 1
Open Access
Immune Checkpoint Inhibitors and Targeted Therapies in Early-Stage Non-Small-Cell Lung Cancer: State-of-the-Art and Future Perspectives
Lucrezia Barcellini, Simone Nardin, G. Sacco, et al.
Cancers (2025) Vol. 17, Iss. 4, pp. 652-652
Open Access
A Response to the Letter to the Editor “Patients With Resectable NSCLC Undergoing Neoadjuvant Chemoimmunotherapy: To Adjuvant or Not to Adjuvant?”
Daniele Marinelli, Filippo Tommaso Gallina
Journal of Thoracic Oncology (2025) Vol. 20, Iss. 3, pp. e43-e44
Closed Access
Neoadjuvant immune checkpoint inhibitors for hepatocellular carcinoma
Vinita Akula, Lily Chen, Yusuf Açıkgöz, et al.
npj Precision Oncology (2025) Vol. 9, Iss. 1
Open Access
Latest Advances in Perioperative care for Resectable Non-small lung cancer
Yuko Oya, Ichidai Tanaka
Respiratory Investigation (2025) Vol. 63, Iss. 4, pp. 532-541
Open Access
Advances in clinical trials on perioperative immune checkpoint inhibitors for resectable non-small cell lung cancer: A comprehensive review
Siyuan Cui, Na Wang, Yangyueying Liang, et al.
International Immunopharmacology (2024) Vol. 141, pp. 112903-112903
Closed Access | Times Cited: 2
Perioperative immunotherapy in nonsmall cell lung cancer
Renzhi Zhang, Chun Zou, Liang Zeng, et al.
Current Opinion in Oncology (2024)
Closed Access | Times Cited: 2
Efficacy and safety of immune checkpoint inhibitors as neoadjuvant therapy in perioperative patients with non-small cell lung cancer: a network meta-analysis and systematic review based on randomized controlled trials
Kaiqi Chen, Xin Wei Wang, Rui Yue, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access | Times Cited: 2
Perioperative immunotherapy for nonsmall cell lung cancer
Jingya Huang, Wenyuan Li, Hui Guo
Current Opinion in Oncology (2024)
Closed Access | Times Cited: 1
Efficacy and safety of perioperative immunotherapy combinations for resectable non-small cell lung cancer: a systematic review and network meta-analysis
Han Yue-Lin, Xiangtian Xiao, Tingting Qin, et al.
Cancer Immunology Immunotherapy (2024) Vol. 73, Iss. 12
Open Access | Times Cited: 1
Temporal Effect on PD‐L1 Detection and Novel Insights Into Its Clinical Implications in Non–Small Cell Lung Cancer
Gopal P. Pathak, Rashmi R. Shah, Mathieu Castonguay, et al.
Cancer Medicine (2024) Vol. 13, Iss. 19
Open Access | Times Cited: 1
Efficacy and safety of PD-1 and PD-L1 inhibitors in advanced colorectal cancer: a meta-analysis of randomized controlled trials
Zhen-Zi Wang, Yuan Liu, Kedi Wang, et al.
BMC Gastroenterology (2024) Vol. 24, Iss. 1
Open Access | Times Cited: 1
Perioperative immunotherapy plus chemotherapy versus chemotherapy alone for patients with resectable pulmonary lymphoepithelioma-like carcinoma
Mengjie Lei, Xuanye Zhang, Lina Hu, et al.
Lung Cancer (2024) Vol. 199, pp. 108057-108057
Open Access | Times Cited: 1
Adaptive medicine, a crucial component of optimized decision making: perspectives from lung cancer management
Wenhua Liang, Ran Zhong, Jianxing He
Translational Lung Cancer Research (2024) Vol. 13, Iss. 6, pp. 1185-1189
Open Access
The efficacy and safety of neoadjuvant immunochemotherapy in resectable stage I-III non-small cell lung cancer: a systematic review and network meta-analysis
Bo Li, Yujia Gu, Weixing Zhao, et al.
Clinical & Translational Oncology (2024)
Closed Access
Perioperative Immunotherapy Plus Chemotherapy Versus Chemotherapy Alone for Patients with Resectable Pulmonary Lymphoepithelioma-Like Carcinoma
Lei Mengjie, Xuan Ye Zhang, Lina Hu, et al.
(2024)
Closed Access
Adjuvant treatment after neoadjuvant immunotherapy in patients with non-small cell lung cancer
Junfeng Zhao, Ying Li, Ruyue Li, et al.
iScience (2024) Vol. 27, Iss. 12, pp. 111281-111281
Open Access
Brief Report: Prognostic impact of adjuvant immunotherapy in patients with resectable non-small cell lung cancer following neoadjuvant chemoimmunotherapy
Yichen Dong, Long Xu, Jialiang Wen, et al.
JTO Clinical and Research Reports (2024) Vol. 6, Iss. 1, pp. 100763-100763
Open Access
Page 1

Scroll to top